Recommendations on dose level selection for repeat dose toxicity studies
-
Published:2022-04-29
Issue:7
Volume:96
Page:1921-1934
-
ISSN:0340-5761
-
Container-title:Archives of Toxicology
-
language:en
-
Short-container-title:Arch Toxicol
Author:
Sewell FionaORCID, Corvaro MarcoORCID, Andrus Amanda, Burke Jonathan, Daston George, Delaney Bryan, Domoradzki Jeanne, Forlini Carole, Green Maia Louise, Hofmann Thomas, Jäckel Sven, Lee Moung Sook, Temerowski Michael, Whalley Paul, Lewis Richard
Abstract
AbstractPrior to registering and marketing any new pharmaceutical, (agro)chemical or food ingredient product manufacturers must, by law, generate data to ensure human safety. Safety testing requirements vary depending on sector, but generally repeat-dose testing in animals form the basis for human health risk assessments. Dose level selection is an important consideration when designing such studies, to ensure that exposure levels that lead to relevant hazards are identified. Advice on dose level selection is provided in test guidelines and allied guidance documents, but it is not well harmonised, particularly for selection of the highest dose tested. This paper further builds on concepts developed in a technical report by the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) which recommends pragmatic approaches to dose selection considering regulatory requirements, animal welfare and state of the art scientific approaches. Industry sectors have differing degrees of freedom to operate regarding dose level selection, depending on the purpose of the studies and the regulatory requirements/legislation, and this is reflected in the overall recommended approaches. An understanding of systemic exposure should be utilised where possible (e.g., through toxicokinetic approaches) and used together with apical endpoints from existing toxicity studies to guide more appropriate dose level selection. The highest dose should be limited to a reasonable level, causing minimal but evident toxicity to the test animals without significantly compromising their well-being. As the science of predictive human exposure further develops and matures, this will provide exciting and novel opportunities for more human-relevant approaches to dose level selection.
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Toxicology,General Medicine
Reference37 articles.
1. Barile FA, Berry SC, Blaauboer B et al (2021) The EU chemicals strategy for sustainability: in support of the BfR position. Arch Toxicol 95:3133–3136. https://doi.org/10.1007/s00204-021-03125-w 2. Beyer BK, Chernoff N, Danielsson BR, Davis-Bruno K, Harrouk W, Hood RD, Janer G, Liminga UW, Kim JH, Rocca M, Rogers J, Scialli AR (2011) ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretation. Birth Def Res B 92:36–51 3. Chapman K, Sewell F, Allais L, Delongeas JL, Donald E, Festag M, Kervyn S, Ockert D, Nogues V, Palmer H, Popovic M, Roosen W, Schoenmakers A, Somers K, Stark C, Stei P, Robinson S (2013) A global pharmaceutical company initiative: an evidence-based approach to define the upper limit of body weight loss in short term toxicity studies. Regul Toxicol Pharmacol 67:27–38 4. Chapman K, Burnett J, Corvaro M, Mitchell D, Robinson S, Sangster T, Sparrow S, Spooner N, Wilson A (2014) Reducing pre-clinical blood volumes for toxicokinetics: toxicologists, pathologists and bioanalysts unite. Bioanalysis 6:2965–2968 5. ECHA (2017) European chemical agency guidance for the implementation of REACH. Guidance on information requirements and chemical safety assessment, chapter R.7C: endpoint specific guidance Version 3.0 (ECHA-17-G-11-EN). EChA, Helsinki, 2017. https://echa.europa.eu/documents/10162/17224/information_requirements_r7c_en.pdf/e2e23a98-adb2-4573-b450-cc0dfa7988e5?t=1498476107907
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|